Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer

Japanese Journal of Clinical Oncology

Volumn 35, Issue 6, 2005, Pages 342-348

  Shin, Sang Joon ^a   Kim, Kyeong Ok ^a   Kim, Min Kyoung ^a   Lee, Kyung Hee ^a   Hyun, Myung Soo ^a   Kim, Keuk Jun ^b   Choi, Joon Hyuk ^b   Song, Hong Seok ^c  

^a Yeungnam University   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

^c Keimyung University   (South Korea)

Author keywords

E cadherins; Pancreatic neoplasms; Urokinase plasminogen activator

Indexed keywords

TUMOR MARKER; UROKINASE; UVOMORULIN; CADHERIN;

ADULT; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS CANCER; PROGNOSIS; PROTEIN EXPRESSION; BIOSYNTHESIS; CANCER INVASION; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; PANCREAS TUMOR; PATHOLOGY; SURVIVAL RATE; VASCULAR TUMOR;

ADULT; AGED; CADHERINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; URINARY PLASMINOGEN ACTIVATOR; VASCULAR NEOPLASMS;

EID: 23844512522     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi094     Document Type: Article

References (28)

1. Kern S, Tempero M, Corley B. Pancreatic Cancer: An Agenda for Action. Report of the Pancreatic Cancer Progress Review Group, NCI; 2001.
2. Cantero D, Friess H, Deflorin J, Zimmermann A, Brundler MA, Riesle E, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997;75: 388-95.
3. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
4. Meyer T, Hart IR. Mechanisms of tumour metastasis. Eur J Cancer 1998;34:214-21.
5. Guilford P. E-cadherin downregulation in cancer: Fuel on the fire? Mol Med Today 1999;5:172-7.
6. Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138: 1059-67.
7. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: A multifunctional role in tumor progression and metastasis. Clin Orthop 2003;(415 Suppl):S46-58.
8. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;27;363:1049-57.
9. Peter FM. Urokinase plasminogen activator system. Clin Orthop 2003;(415 Suppl):S46-58.
10. Chan AO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, et al. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 2001;48:808-11.
11. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 1993;142:987-93.
12. Palacios J, Benito N, Pizarro A, Suarez A, Espada J, Cano A, et al. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. Am J Pathol 1995;146:605-12.
13. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 1996;105: 394-402.
14. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-33.
15. Matsui S, Shiozaki H, Inoue M, Tamura S, Doki Y, Kadowaki T, et al. Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer. Virchows Arch 1994;424:375-81.
16. Shimazui T, Schalken JA, Giroldi LA, Jansen CF, Akaza H, Koiso K, et al. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res 1996;56:4154-8.
17. Dorudi S, Hanby AM, Poulsom R, Northover J, Hart IR. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 1995;71:614-6.
18. Pignatelli M, Ansari TW, Gunter P, Liu D, Hirano S, Takeichi M, et al. Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994;174:243-8.
19. He CJ, Rebibou JM, Peraldi MN, Meulders Q, Rondeau E. Growth factor-like effect of urokinase type plasminogen activator in human renal cells. Biochem Biophys Res Commun 1991;176: 1408-16.
20. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-9.
21. Tatsuta S, Tanaka S, Haruma K. Combined expression of urokinase-type plasminogen activator and proliferating cell nuclear antigen at the deepest invasive portion correlates with colorectal cancer prognosis: clinical studies. Int J Oncol 1997;10:125-9.
22. Nekarda H, Schmitt M, Ulm K. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-7.
23. Kobayashi H, Gotoh J, Shinohara H, Moniwa N, Terao T. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Thromb Haemostasis 1994;71: 474-80.
24. Gleeson NC, Gonsalves R, Bonnar J. Plasminogen activator inhibitors in endometrial adenocarcinoma. Cancer 1993;72:1670-2.
25. Hasui Y, Marutsuka K, Asada Y, Osada Y. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology 1996;47:34-7.
26. Pedersen H, Brunner N, Francis D. Prognostic impact of urokinase, urokinase receptor. Cancer Res 1994;54:4671-5.
27. Lee KH, Hyun MS, Kim JR. Invasive-metastasis by hepatocyte growthfactor/ c-Met signaling concomitant with induction of urokinase plasminogen activator in human pancreatic cancer: Role as therapeutic target. Cancer Res Treat 2003;35:207-12.
28. Yonemura Y, Nojima N, Kaji M, Fujimura T, Itob H, et al. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer 1995;76:941-53.